Search clinical trials for: Ropinirole

Total 73 results

GlaxoSmithKline

Completed

Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)

Restless Legs Syndrome | Restless Legs Syndrome (RLS)

United States
GlaxoSmithKline

Completed

Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease

Parkinson Disease

Japan
GlaxoSmithKline

Terminated

A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.

Parkinson Disease

Japan
GlaxoSmithKline

Completed

A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's

Parkinson Disease

Spain, France, Bulgaria, United Kingdom, Germany, Hungary, Russian Federation, South Africa, Italy, Canada, Czechia, Poland, Romania, Ukraine
Titan Pharmaceuticals

Terminated

Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole

Parkinson Disease

United States
St. Luke's-Roosevelt Hospital Center
GlaxoSmithKline

Completed

Treating Sexual Dysfunction From Selective Serotonin Reuptake Inhibitor (SSRI) Medication: a Study Comparing Requip CR to Placebo

Sexual Dysfunction

United States
GlaxoSmithKline

Completed

Clinical Evaluation of Ropinirole CR-RLS ( SK&F101468)Tablets in Restless Legs Syndrome

Restless Legs Syndrome

Japan
Lupin Ltd.

Completed

Bioequivalence Study of Ropinirole Hydrochloride CR 2mg Tablets of Lupin Limited, India, With REQUIP XL of GlaxoSmithKline Research Triangle Park, in Healthy, Adult, Male, Subjects Under Fasting Conditions

Pharmacokinetic Study

India
Lupin Ltd.

Completed

Two Way Cross Over BE Fasting Pilot Study of Ropinirole Hydrochloride CR 2mg Tablets

Pharmacokinetic Study

India
Lupin Ltd.

Completed

Bioequivalence Study of Ropinirole Hydrochloride CR 2mg Tablets of Lupin Limited, India, With REQUIP XL of GlaxoSmithKline Research Triangle Park, in Healthy, Adult, Male, Subjects Under Fed Conditions

Pharmacokinetic Study

India
Sheba Medical Center
Jerusalem Mental Health Center

Unknown

A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression.

Bipolar Disorder | Major Depressive Disorder

Israel
Cambridge Health Alliance
GlaxoSmithKline; Emory University

Completed

Ropinirole in the Treatment of Bipolar Depression

Bipolar Disorder

United States
Agarwal, Pinky, M.D.
GlaxoSmithKline; Colorado Neurology

Unknown

Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease

Parkinson's Disease

United States
Roxane Laboratories

Completed

A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions

Parkinson's Disease | Restless Leg Syndrome
GlaxoSmithKline

Completed

A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syndrome (RLS)

Restless Legs Syndrome

United States
GlaxoSmithKline

Completed

Fibromyalgia Study In Adults

Fibromyalgia Syndrome, Primary

Italy, Belgium, Finland, Germany, Netherlands, United Kingdom, France, Denmark, Sweden
GlaxoSmithKline

Completed

A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease (TANDEM-662)

Parkinson Disease

United States, Estonia, Korea, Republic of, Russian Federation, Slovakia
GlaxoSmithKline

Completed

Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome

Restless Legs Syndrome

United States, Canada
Istituti Fisioterapici Ospitalieri
University of Bologna

Completed

Evaluation of the Efficacy of Acitretin Therapy for Nail Psoriasis

Psoriasis

Italy
GlaxoSmithKline

Completed

A Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets Manufactured at Crawley and Aranda

Parkinson Disease

Belgium
GlaxoSmithKline

Completed

12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome ((CR-RLS))

Restless Legs Syndrome | Restless Legs Syndrome (RLS)

United States
Stanford University
GlaxoSmithKline; Duke University

Completed

Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression

Depressive Disorder, Major

United States
Pfizer

Completed

Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.

Parkinson Disease

United States, Argentina, Mexico, Puerto Rico
Roxane Laboratories

Completed

A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions

Parkinson's Disease | Restless Leg Syndrome
GlaxoSmithKline

Completed

Ropinirole Tablets In Young Patients With Restless Legs Syndrome

Restless Legs Syndrome

United States, Belgium, France
GlaxoSmithKline

Completed

RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole

Restless Legs Syndrome | Restless Legs Syndrome (RLS)

Spain, United States, Belgium, Sweden, Australia, Netherlands, United Kingdom, Italy, Austria, Germany, Denmark, France, Norway
GlaxoSmithKline

Terminated

Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With Haemodialysis (Including Haemofiltration and Haemodiafiltration)

Restless Legs Syndrome

Japan
GlaxoSmithKline

Completed

Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome

Restless Legs Syndrome

United States, Canada
GlaxoSmithKline

Completed

Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164

Parkinson Disease

United States
GlaxoSmithKline

Completed

An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease

Parkinson's Disease | Parkinson Disease

United States, Spain, Poland, France, Belgium, Hungary, United Kingdom, Italy, Czech Republic
Seoul National University Hospital

Completed

Study to Compare the Effect of Ropinirole Prolonged Release Once-daily Versus Twice-daily

Parkinson Disease

Korea, Republic of
University of California, Irvine
GlaxoSmithKline

Completed

Trial of Ropinirole in Motor Recovery After Stroke

Hemiparesis | Cerebrovascular Accident

United States
GlaxoSmithKline

Completed

A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole

Restless Legs Syndrome

United States, United Kingdom
GlaxoSmithKline

Completed

Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's

Parkinson's Disease | Parkinson Disease | Dyskinesias

United States
The University of Texas Health Science Center,...

Completed

Cognitive Remediation for Cocaine Dependence

Cocaine Dependence

United States
Teva Pharmaceuticals USA

Completed

The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fed Conditions

Healthy

United States
Teva Pharmaceuticals USA

Completed

Ropinirole 0.25 mg Tablets Under Fasting Conditions

Healthy

United States
GlaxoSmithKline

Completed

Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD)

Parkinson Disease

Japan
Population Health Research Institute

Completed

DIalysis Symptom COntrol-Restless Legs Syndrome Trial (DISCO-RLS)

Restless Legs Syndrome | End Stage Renal Disease

Canada
GlaxoSmithKline

Completed

A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease (TANDEM-569)

Parkinson Disease

United States, Korea, Republic of, Estonia, Russian Federation, Slovakia, Argentina, Chile
Bristol-Myers Squibb

Recruiting

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1)

Systemic Lupus Erythematosus

United States, Brazil, China, Germany, Italy, France, Mexico, Poland, Puerto Rico, Argentina, Canada, Colombia, Hong Kong, Peru, Romania, Portugal, Korea, Republic of, Turkey, Ireland, India, Lithuania, Bulgaria, Slovakia
Bristol-Myers Squibb

Active, not recruiting

A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

Lupus Erythematosus, Discoid | Lupus Erythematosus, Subacute Cutaneous

Mexico, Argentina, Australia, United States, France, Germany, Poland, Taiwan
Desitin Arzneimittel GmbH
FGK Clinical Research GmbH

Completed

Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists (PIVICOG-PD)

Idiopathic Parkinson's Disease

Germany
Mayo Clinic
National Cancer Institute (NCI)

Completed

Acitretin in Preventing Skin Cancer in Patients at High Risk for Skin Cancer

Non-melanomatous Skin Cancer
GlaxoSmithKline

Completed

Ropinirole PR Pharmacokinetics Study Among Chinese Healthy Subjects

Parkinson Disease

China
GlaxoSmithKline

Completed

Restless Legs Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole And The Effect Of Food

Restless Legs Syndrome

Germany, South Africa
University of Turku

Unknown

Effect of Ropinirole Hydrochloride in Progressive Myoclonic Epilepsy of Unverricht-Lundborg Type

Unverricht-Lundborg Syndrome

Finland
GlaxoSmithKline

Completed

Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole

Parkinson Disease

Germany, South Africa
GlaxoSmithKline

Completed

The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome

Restless Legs Syndrome | Moderate to Severe Idiopathic Restless Legs Syndrome (RLS)

Germany
GlaxoSmithKline

Completed

A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome

Restless Legs Syndrome | Restless Legs Syndrome (RLS)

United States

3

Subscribe